Key result
Subcutaneous octreotide controls recurrent GI bleeding in a patient with an LVAD.
Why the study?
Does subcutaneous octreotide resolve recurrent gastrointestinal bleeding in a patient with a HeartWare LVAD?
Case Report (n=1)
Does subcutaneous octreotide resolve recurrent gastrointestinal bleeding in a patient with a HeartWare LVAD?
Subcutaneous octreotide may be an effective management strategy for recurrent gastrointestinal bleeding in patients with a HeartWare LVAD.
May support octreotide for refractory GI bleeding in LVAD patients; leaves open confirmation in prospective trials.
HeartWare is a third generation left ventricular assist device (LVAD), widely used for the management of advanced heart failure patients. These devices are frequently associated with a significant risk of gastrointestinal (GI) bleeding. The data for the management of patients with LVAD presenting with GI bleeding is limited. We describe a 56-year-old lady, recipient of a HeartWare device, who experienced recurrent GI bleeding and was successfully managed with subcutaneous (SC) formulations of octreotide.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2014) conducted a case report in Recurrent gastrointestinal bleeding with a HeartWare LVAD (n=1). Subcutaneous octreotide was evaluated on Management of recurrent GI bleeding. Subcutaneous octreotide successfully managed recurrent gastrointestinal bleeding in a 56-year-old female patient with a HeartWare left ventricular assist device.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: